“…Finally, PPAR-dependent signal transduction pathway may be effectively modulated in the future by means of siRNA or antisense methodologies, or by selective PPAR modulators, able to exert most of the benefits, while reducing the adverse effects displayed by full PPAR agonists [136]. Wy-14,643 hepatocytes [98] perfluoroctanoic acid liver cancer cells [5] Nafenopin liver cancer cells [3] BR931 liver cancer cells [6] conjugated linoleic acid liver cancer cells [138] TDZ18 lymphocytic leukemia [139] MCC-555 colon cancer cells [140] PPAR/ GW0742 colon cancer cells [141] PPAR TDZ (troglitazone, rosiglitazone, ciglitazone, pioglitazone, TDZ18, MCC-555) osteoblasts, promyelocytic leukaemia, lymphocytic leukaemia, colon, breast, liver, thyroid, ovarian, and lung cancer [7,8,139,140,[142][143][144] 15d-PGJ2 neurons, B-lymphocytes, Blymphoma,promyelocytic leukaemia, colon, breast, thyroid and lung cancer (142,143,(145)(146)(147) DEHP Sertoli cells [148] DHEP = Di(2-ethylhexyl) phthalate; TDZ = thiazolidindione;…”